Triangle Pharmaceuticals (VIRS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Triangle Pharmaceuticals (VIRS)

VIRS 40.03

0.0%

Oct 10 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: (no name provided) who wrote (12)	7/3/1997 7:33:00 PM
From: John Metcalf	of 34

Good point, Kafka666. Still, companies do raise money without giving up much. For example, they can sell access to platform technologies without giving away the rights to their own discovery programs. Sometimes, they even get royalties on discoveries that devolve from their platforms. It is very common as well to do contract research in an area where the company has expertise, while the researchers advance the work of the research boutique and the payor company simultaneously. Companies with products can sign co-promotion agreements in which the payor company's product revenue pays for the small company's developing sales force. An example of this is Gilead's agreement with Roche to co-promote Roferon-A for hepatitis C. The first two models seem very likely for a strong research organization like VIRS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next